AIM
ALNY icon

Achmea Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Achmea Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,847
Closed -$1.38M – 358
2024
Q4 		$1.38M Buy
5,847
+105
+2% +$27.6K 0.02% 320
2024
Q3 		$1.58M Buy
5,742
+1,728
+43% +$450K 0.03% 326
2024
Q2 		$975K Hold
4,014
– – 0.02% 354
2024
Q1 		$599K Hold
4,014
– – 0.01% 397
2023
Q4 		$769K Sell
4,014
-4,911
-55% -$837K 0.02% 416
2023
Q3 		$1.58M Sell
8,925
-184
-2% -$35.1K 0.03% 341
2023
Q2 		$1.73M Buy
9,109
+1,698
+23% +$337K 0.04% 350
2023
Q1 		$1.48M Buy
7,411
+2,919
+65% +$614K 0.04% 339
2022
Q4 		$1M Buy
4,492
+4,308
+2,341% +$919K 0.03% 400
2022
Q3 		$37K Hold
184
– – ﹤0.01% 573
2022
Q2 		$27K Hold
184
– – ﹤0.01% 579
2022
Q1 		$30K Hold
184
– – ﹤0.01% 593
2021
Q4 		$31K Hold
184
– – ﹤0.01% 322
2021
Q3 		$35K Buy
+184
New +$34.5K ﹤0.01% 548
2020
Q3 		– Sell
-12,459
Closed -$1.84M – 483
2020
Q2 		$1.84M Sell
12,459
-6,360
-34% -$857K 0.06% 190
2020
Q1 		$2.05M Buy
18,819
+11,425
+155% +$1.32M 0.09% 148
2019
Q4 		$852K Hold
7,394
– – 0.03% 388
2019
Q3 		$595K Hold
7,394
– – 0.02% 413
2019
Q2 		$537K Hold
7,394
– – 0.02% 435
2019
Q1 		$691K Hold
7,394
– – 0.03% 371
2018
Q4 		$539K Hold
7,394
– – 0.02% 380
2018
Q3 		$647K Hold
7,394
– – 0.02% 410
2018
Q2 		$728K Hold
7,394
– – 0.03% 399
2018
Q1 		$880K Hold
7,394
– – 0.03% 395
2017
Q4 		$939K Buy
+7,394
New +$929K 0.03% 386

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Achmea Investment Management's ALNY Position: Q1 2025 in Review

Achmea Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 5,847 shares — an estimated $1.38M sold.

Achmea Investment Management first reported a position in ALNY in Q4 2017 and held it in 25 quarters. The position peaked at $2.05M in Q1 2020. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Achmea Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Achmea Investment Management sold 5,847 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $1.38M.
  • Achmea Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2017 and held it in 25 quarters.
  • Achmea Investment Management's Alnylam Pharmaceuticals position peaked at $2.05M in Q1 2020.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Achmea Investment Management's 13F filing for Q1 2025, filed 24 Apr 2025.